Compare Amylx Pharmaceuticals Inc (AMLX) vs Moody's Corporation (MCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Moody's Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Moody's Corporation trades at $480.01 (market cap $85.12B). The key difference: Moody's Corporation is far larger — about 43× Amylx Pharmaceuticals Inc's market cap, and Moody's Corporation pays a 0.85% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MCO | |
|---|---|---|
Market Cap | $1.98B | $85.12B |
Sector | Health | Financials |
52-Week High | $18.70 | $539.61 |
52-Week Low | $7.64 | $412.23 |
Enterprise Value | $1.70B | $90.92B |
Dividend Yield | — | 0.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
MCO trades at $487.28, up 0.05% on the day, with a bullish technical signal supported by moving averages and strong fundamentals. The company reported Q1 2026 EPS of $4.33, beating estimates, and maintains robust profitability with a 31.69% net income margin. Recent news highlights Moody's AI initiatives, including new AI skills and integrations, positioning for growth in credit analytics. The stock is near its 52-week high, with support at $481 and resistance at $490.
Outlook remains positive with a consensus price target of $539.40, implying 11% upside, driven by earnings momentum and AI adoption. Risks include high valuation multiples (P/E 34.96) and dependence on debt issuance cycles. Institutional sentiment is bullish with 56% buy ratings, but overbought RSI levels suggest near-term consolidation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
